The development-stage biopharma is bouncing back from a recent stock dip.
News & Analysis: Arcus Biosciences, Inc.
Investors expecting a buyout offer were disappointed by the collaboration agreement Gilead Sciences offered.
The deal gives Gilead access to a new pipeline of potential cancer immunotherapies.
The two companies are apparently discussing either an equity purchase or some other form of cooperation.
Arcus Biosciences stock is on fire in response to a possible partnership deal with Gilead Sciences.
Efforts to contain COVID-19 are putting the entire biopharmaceutical industry in a jam.
See if they can keep climbing.
Find out which of these stocks benefited from a major strategic move.
Even in a surging market, these stocks fell. Find out why.